These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 20689698

  • 1. Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
    Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC.
    Drug Des Devel Ther; 2010 Jul 21; 4():117-26. PubMed ID: 20689698
    [Abstract] [Full Text] [Related]

  • 2. Oral therapy for multiple sclerosis--sea change or incremental step?
    Carroll WM.
    N Engl J Med; 2010 Feb 04; 362(5):456-8. PubMed ID: 20089958
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS.
    J Neurol Sci; 2011 Dec 04; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [Abstract] [Full Text] [Related]

  • 7. Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
    Voon V, Saiva L, O'Kelly S, Keane D.
    Eur J Clin Pharmacol; 2014 Mar 04; 70(3):373-5. PubMed ID: 24309839
    [No Abstract] [Full Text] [Related]

  • 8. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
    Vasiliou S.
    Drugs Today (Barc); 2010 May 04; 46(5):315-25. PubMed ID: 20517533
    [Abstract] [Full Text] [Related]

  • 9. Fingolimod for relapsing multiple sclerosis: an update.
    Horga A, Castilló J, Montalban X.
    Expert Opin Pharmacother; 2010 May 04; 11(7):1183-96. PubMed ID: 20367536
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.
    Al-Hashel J, Ahmed SF, Behbehani R, Alroughani R.
    CNS Drugs; 2014 Sep 04; 28(9):817-24. PubMed ID: 25011422
    [Abstract] [Full Text] [Related]

  • 13. Oral treatment for multiple sclerosis.
    Killestein J, Rudick RA, Polman CH.
    Lancet Neurol; 2011 Nov 04; 10(11):1026-34. PubMed ID: 22014437
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.
    Fazekas F, Berger T, Fabjan TH, Ledinek AH, Jakab G, Komoly S, Kraus J, Kurča E, Kyriakides T, Lisý L, Milanov I, Panayiotou P, Jazbec SS, Taláb R, Traykov L, Turčáni P, Vass K, Vella N, Havrdová E.
    Wien Med Wochenschr; 2012 Aug 04; 162(15-16):354-66. PubMed ID: 22895849
    [Abstract] [Full Text] [Related]

  • 16. Emerging therapies in relapsing-remitting multiple sclerosis.
    Marriott JJ, O'Connor PW.
    Rev Recent Clin Trials; 2010 Sep 04; 5(3):179-88. PubMed ID: 20500147
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fingolimod for multiple sclerosis.
    Drug Ther Bull; 2012 Feb 04; 50(2):18-20. PubMed ID: 22329953
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.